Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Building on critical findings from our research streams, we are initiating new drug discovery programmes. Many of our researchers are engaged in target discovery and target validation research – elucidating molecular pathways that can be manipulated for disease modification.

© Martin Phelps

We undertake early phase clinical trials with a focus on detailed phenotyping of patient responses. Besides work on small molecule and antibody therapies, we have expertise in gene therapy. Further down the drug discovery pipeline we lead a large number of clinical trials in a range of different diseases – from those that affect millions in the UK such as diabetes and heart disease, through to rarer conditions such as Cystic Fibrosis and leukaemia.

Groups within this theme